Granules India

Hyderabad, India Founded: 1984 • Age: 42 yrs Listed
CDMO focused on manufacturing of active pharmaceutical ingredients
Request Access
Report Incorrect Data
Page last updated

About Granules India

Granules India is a publicly listed company based in Hyderabad (India) founded in 1984 by Krishna Prasad Chigurupati. The company has 6,170 employees. Granules India has completed 2 acquisitions, including Auctus Pharma and Senn Chemicals. Its chief executive, as recorded, is KVS Ram Rao. Its website granulesindia.com draws about 14 thousand monthly visits. Its Indian entity Granules India Limited reported revenue of ₹5,386 Cr. Its focus areas include Traditional Pharmaceuticals and Active Pharmaceutical Ingredients.

Company details

CDMO focused on manufacturing of active pharmaceutical ingredients. It offers a wide range of products include Paracetamol, Ibuprofen, Metformin, Guaifenesin, Methocarbamol, Pharmaceutical Formulation Intermediates and Finished Dosages.

Recognitions & Rankings of Granules India

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#384
Valuation
₹14,060 Cr
2023 #454 2022 #348 2021 #389
  • Headquarters Hyderabad, India
  • Employees 6,170
  • Founders Krishna Prasad Chigurupati
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website granulesindia.com
  • Social LinkedIn X Facebook
  • Legal Name Granules India Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹22,841 Cr

    GRANULES · NSE

  • Share Price
    ₹839.75

    +0.29% today

  • Revenue
    ₹5,366 Cr

    FY 2025-26 · +19.7% YoY

  • EBITDA
    ₹1,175 Cr

    Margin 21.9%

  • Net Profit
    ₹605 Cr

    FY 2025-26 · +30.0% YoY

  • P/E (TTM)
    35.3x

    P/B 3.7x

  • ROE
    13.5%

    ROCE 15.2%

  • Debt / Equity
    0.34

    Interest cover 13.0x

  • Employee Count
    6,170
  • Investments & Acquisitions
    Auctus Pharma

    & 1 more

Board of directors of Granules India Limited (Granules India)

Granules India Limited is the primary company behind Granules India. The board of Granules India Limited currently have 11 directors; the longest-serving is Krishna Prasad Chigurupati, appointed in 1994. 23 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Krishna Prasad Chigurupati
DIN 00020180
Managing Director31 Aug 199432 yrs 2 moGranules India Limited
Harsha Chigurupati
DIN 01606477
Whole-time director26 Jul 201016 yrs 3 moGranules India Limited
Umadevi Chigurupati
DIN 00737689
Whole-time director31 May 201214 yrs 5 moGranules India Limited
Basava Sankar Rao Kolli
DIN 05167550
Director19 Feb 201313 yrs 8 moGranules India Limited
Arun Sawhney
DIN 01929668
Director29 Oct 20188 yrsGranules India Limited
Saumen Chakraborty
DIN 06471520
Director13 Dec 20214 yrs 10 moGranules India Limited
Palepu Sucharita Rao
DIN 07807717
Director22 Dec 20214 yrs 10 moGranules India Limited
Kapil Mehan
DIN 01215092
Director16 May 20233 yrs 5 moGranules India Limited
Sethurathnam Ravi
DIN 00009790
Director23 Jan 20242 yrs 9 moGranules India Limited
Priyanka Chigurupati
DIN 01793431
Whole-time director23 Jan 20242 yrs 9 moGranules India Limited
Rajiv Pritidas Kakodkar
DIN 01519590
Director20 Feb 20242 yrs 8 moGranules India Limited

People of Granules India

104 people are tracked at Granules India (38 in leadership, 7 in board & advisors, 59 in team); the tracked headcount is 6,170.

NameRoleGroup
Krishna Prasad Chigurupati
Founder & Managing DirectorLeadership
KVS Ram Rao
CEOLeadership
Uma Devi Chigurupati
Executive DirectorLeadership
Gsr Prasad
COOLeadership
Ramraj Rangarajalu
President & Head, Formulations OperationsLeadership
Priyanka Chigurupati
Executive Director, Granules Pharmaceuticals Inc. & Granules UsaLeadership
G. N. Prashanth
SVP & Head Corporate QualityLeadership
Syed Ziauddin
Assistant General Manager - HR & AdminLeadership
Abhinay Kesanapalli
Deputy General Manager Finance AccountLeadership
Rajkumar Grandhi
General Manager FinanceLeadership
Srinivas Pullela
Chief Technology OfficerLeadership
Hema Vara Sankara Rao Banala
Asst. General ManagerLeadership
Sivaram Prasad Guntamukkala
Chief Operating Officer (coo)Leadership
Vithal Bandi
Head Production Pharmaceutical Formulation IntermediatesLeadership
Deep Sagar
Global Head, LegalLeadership
Mayur Phadke
Director Of OperationsLeadership
Kasula Lakshminarayana
General ManagerLeadership
Jettem Sathyanarayana
Vice President - CommercialLeadership
Aparna Reddy Muthumula
Head Of Legal & GMLeadership
Sampath Kumar Upparapalli
Senior Vice PresidentLeadership

84 more people are available in the full profile.

Premium access

Complete people profiles for Granules India

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Granules India

Granules India is a publicly listed company on the NSE with ticker symbol GRANULES in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Jun 2005
  • Listed onNSE: GRANULES
  • Listed entityGranules India Limited
  • Exchange sectorHealth technology
  • ISININE101D01020
  • Share price₹809.10 (-0.66% on the day) · 2026-10-14
  • Market capitalisation₹20,150 Cr
  • Price to earnings30.1
  • EPS (diluted, trailing year)₹26.92
  • Dividend yield0.22%
  • Volume (last session)404,587

Financials of Granules India

Exchange-reported figures of Granules India Limited, the listed company behind Granules India (NSE: GRANULES).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹5,366 Cr
+19.7% YoY
EBITDA
₹1,175 Cr
+24.3% YoY
Profit After Tax
₹605 Cr
+30.0% YoY
Net Worth
₹5,085 Cr
+36.9% YoY
Total Assets
₹6,645 Cr
+27.7% YoY
Total Debt
₹1,512 Cr
+3.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue5,3664,4824,5064,5123,7653,2382,599
Revenue growth+19.7%-0.6%-0.1%+19.8%+16.3%+24.6%-
EBITDA1,175945856914722855525
EBITDA margin+21.9%+21.1%+19.0%+20.3%+19.2%+26.4%+20.2%
Profit before tax785660547687558704451
Net profit605465407518416550316
Net profit margin+11.3%+10.4%+9.0%+11.5%+11.1%+17.0%+12.1%
EPS (₹)24.0120.6816.7221.3416.6422.1813.19
Balance sheet
Total assets6,6455,2024,5784,0003,7223,0472,757
Net worth5,0853,7163,2262,8352,5872,1731,844
Total debt1,5121,4551,3151,1361,106849892
Cash & bank949596386313409271284
Net working capital2,7302,0961,9861,6781,7281,3321,206
Cash flow
Cash from operations793867439739332432476
Cash from investing(758)(689)(358)(192)(379)(277)(160)
Cash from financing379(92.51)7.66(440)190(299)(213)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,4771,4711,3881,2971,2101,1971,138967
Revenue growth (YoY)+22.0%+22.8%+22.0%+34.2%+2.6%---
Other income2.2724.69(3.64)(1.15)16.3532.675.683.26
EBITDA339352308278221252230203
EBITDA margin+23.1%+24.2%+22.4%+21.5%+18.3%+21.1%+20.3%+21.3%
Depreciation79.6581.7573.5372.0268.8563.5056.6152.52
Interest21.1232.6928.6929.1923.7823.9826.5725.67
Profit before tax240262202176145198153128
Tax60.4460.7952.0345.2631.8845.5235.1931.15
Net profit18020215013111315211897.24
EPS (₹)7.128.236.195.384.646.274.854.01
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,4743,0303,7553,9313,2383,1352,310
Revenue growth+14.7%-19.3%-4.5%+21.4%+3.3%+35.7%-
EBITDA712565801838645861494
EBITDA margin+20.5%+18.6%+21.3%+21.3%+19.9%+27.5%+21.4%
Profit before tax536427591664520733553
Net profit410283438500390553319
Net profit margin+11.8%+9.3%+11.7%+12.7%+12.1%+17.6%+13.8%
EPS (₹)16.1713.1717.9920.6115.5822.3217.47
Balance sheet
Total assets5,2504,3334,2143,6523,6203,0362,724
Net worth4,3993,4033,1112,6992,5312,1631,812
Total debt8288991,0659231,061849891
Cash & bank276170228203355241272
Net working capital1,5831,4991,8731,4901,6081,2571,097
Cash flow
Cash from operations643823317664280375495
Cash from investing(1,030)(554)(302)(96.71)(318)(233)(165)
Cash from financing444(340)26.14(519)151(296)(212)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue802877895892810768842568
Revenue growth (YoY)-1.0%+14.2%+6.3%+57.0%-4.9%---
Other income13.7816.6912.087.8913.1561.245.612.78
Total expenses670702701680679651674465
EBITDA131175194211131117168103
EBITDA margin+16.9%+20.6%+22.4%+24.1%+16.5%+16.0%+20.0%+18.4%
Depreciation39.0643.6440.5940.7439.5137.9737.6634.75
Interest9.6115.7115.4016.6513.6713.4917.2114.56
Profit before tax96.5613215016291.4512711956.07
Tax24.8233.1038.8041.2921.9632.6428.4914.68

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 01 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,4771,4711,3881,2971,2101,1971,138967
Revenue growth (YoY)+22.0%+22.8%+22.0%+34.2%+2.6%---
Other income2.2724.69(3.64)(1.15)16.3532.675.683.26
EBITDA339352308278221252230203
EBITDA margin+23.1%+24.2%+22.4%+21.5%+18.3%+21.1%+20.3%+21.3%
Depreciation79.6581.7573.5372.0268.8563.5056.6152.52
Interest21.1232.6928.6929.1923.7823.9826.5725.67
Profit before tax240262202176145198153128
Tax60.4460.7952.0345.2631.8845.5235.1931.15
Net profit18020215013111315211897.24
EPS (₹)7.128.236.195.384.646.274.854.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue5,3664,4824,5064,5123,7653,2382,599
Revenue growth+19.7%-0.6%-0.1%+19.8%+16.3%+24.6%-
Other income20.3343.674.4013.7817.6126.8889.79
Total expenses4,1913,5363,6503,5983,0432,3822,073
Employee cost849620550420366324259
EBITDA1,175945856914722855525
EBITDA margin+21.9%+21.1%+19.0%+20.3%+19.2%+26.4%+20.2%
Depreciation296226207184159151137
Interest11410310655.9323.2126.2827.02
Profit before tax785660547687558704451
Tax190159142171145155116
Net profit605465407518416550316
Net profit margin+11.3%+10.4%+9.0%+11.5%+11.1%+17.0%+12.1%
EPS (₹)24.0120.6816.7221.3416.6422.1813.19
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.7824.2524.2424.2024.8024.7725.42
Reserves & surplus4,6953,6913,2012,8112,5622,1491,818
Shareholders' funds (net worth)5,0853,7163,2262,8352,5872,1731,844
Minority interest0.000.000.000.000.560.000.00
Secured loans1,144974845792816685804
Unsecured loans36948147034429116488.18
Total debt1,5121,4551,3151,1361,106849892
Total liabilities6,6455,2024,5784,0003,7223,0472,757
Assets
Gross block4,9883,8823,3522,9812,4622,1451,875
Net block3,2502,4262,0961,9111,5411,3321,204
Capital work in progress410440272239356239294
Investments0.8422.0421.5221.2119.6718.9919.34
Inventories1,6731,3431,3011,149979782438
Sundry debtors909942986949925765662
Cash & bank balances949596386313409271284
Loans & advances236234232163192178244
Total current assets3,7683,1152,9052,5742,5051,9971,629
Total current liabilities1,0381,019919897777665423
Net working capital2,7302,0961,9861,6781,7281,3321,206
Total assets6,6455,2024,5784,0003,7223,0472,757
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash46638129218541.8418683.02
Net cash from operating activities793867439739332432476
Net cash from investing activities(758)(689)(358)(192)(379)(277)(160)
Net cash from financing activities379(92.51)7.66(440)190(299)(213)
Net change in cash41485.0189.54107143(144)103
Closing cash949596386313409271284
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.7%-0.6%-0.1%+19.8%+16.3%+24.6%-
EBITDA growth+24.3%+10.4%-6.3%+26.5%-15.6%+62.8%-
PBT growth+18.9%+20.6%-20.4%+23.2%-20.8%+56.1%+38.6%
Net income growth+30.0%+14.4%-21.4%+24.3%-24.3%+74.2%-
Revenue CAGR (3Y)+6.0%+6.0%+11.7%+20.2%+18.2%+24.3%+22.6%
EBITDA CAGR (3Y)+8.7%+9.4%+0.0%+20.3%+23.4%+45.4%+20.7%
Profitability & leverage
Net income margin+11.1%+11.2%+9.0%+11.5%+11.0%+17.0%+12.9%
Return on capital employed+15.2%+15.6%+15.2%+19.3%+17.2%+25.2%+18.1%
Return on net worth+13.5%+14.5%+13.4%+19.1%+17.3%+27.4%+19.9%
Debt / equity0.340.400.400.410.410.430.56
Long-term debt / equity0.110.090.060.090.120.190.27
Interest cover13.0114.3416.317.674.123.736.96
Efficiency & per share
Fixed asset turnover1.211.241.421.661.631.611.55
Inventory turnover3.563.393.684.244.285.306.32
Debtors turnover5.804.654.664.824.454.543.89
EPS (₹)24.0120.6816.7221.3416.6422.1813.19
Dividend per share (₹)1.751.501.501.501.501.501.00
Book value per share (₹)190.45153.19133.08117.13104.2987.7572.52
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue802877895892810768842568
Revenue growth (YoY)-1.0%+14.2%+6.3%+57.0%-4.9%---
Other income13.7816.6912.087.8913.1561.245.612.78
Total expenses670702701680679651674465
EBITDA131175194211131117168103
EBITDA margin+16.9%+20.6%+22.4%+24.1%+16.5%+16.0%+20.0%+18.4%
Depreciation39.0643.6440.5940.7439.5137.9737.6634.75
Interest9.6115.7115.4016.6513.6713.4917.2114.56
Profit before tax96.5613215016291.4512711956.07
Tax24.8233.1038.8041.2921.9632.6428.4914.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,4743,0303,7553,9313,2383,1352,310
Revenue growth+14.7%-19.3%-4.5%+21.4%+3.3%+35.7%-
Other income49.8071.435.789.9317.5113.72188
Total expenses2,7622,4652,9543,0932,5942,2741,816
Employee cost384342333278248234193
EBITDA712565801838645861494
EBITDA margin+20.5%+18.6%+21.3%+21.3%+19.9%+27.5%+21.4%
Depreciation164146144146126118102
Interest61.4462.7872.0038.6716.3523.7726.86
Profit before tax536427591664520733553
Tax135108155165133180109
Net profit410283438500390553319
Net profit margin+11.8%+9.3%+11.7%+12.7%+12.1%+17.6%+13.8%
EPS (₹)16.1713.1717.9920.6115.5822.3217.47
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.7824.2524.2424.2024.8024.7725.42
Reserves & surplus4,0093,3793,0872,6752,5062,1381,786
Shareholders' funds (net worth)4,3993,4033,1112,6992,5312,1631,812
Secured loans594479701792816685804
Unsecured loans23442036413124516486.99
Total debt8288991,0659231,061849891
Total liabilities5,2504,3334,2143,6523,6203,0362,724
Assets
Gross block2,6592,4992,3122,2011,9491,6931,523
Net block1,4531,4051,3241,3301,171985927
Capital work in progress11812152.9463.46211164130
Investments2,0301,282941677597592445
Inventories626648579593591462344
Sundry debtors1,2471,2951,6331,3721,2101,014627
Cash & bank balances276170228203355241272
Loans & advances146174194149174161232
Total current assets2,2962,2872,6342,3182,3311,8781,475
Total current liabilities713788761828723621377
Net working capital1,5831,4991,8731,4901,6081,2571,097
Total assets5,2504,3334,2143,6523,6203,0362,724
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash15222318213420.0317456.42
Net cash from operating activities643823317664280375495
Net cash from investing activities(1,030)(554)(302)(96.71)(318)(233)(165)
Net cash from financing activities444(340)26.14(519)151(296)(212)
Net change in cash57.75(70.74)41.3347.50114(154)118
Closing cash276170228203355241272
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.7%-19.3%-4.5%+21.4%+3.3%+35.7%-
EBITDA growth+26.1%-29.5%-4.4%+30.0%-25.2%+74.3%-
PBT growth+25.4%-27.8%-10.9%+27.8%-29.1%+32.5%+128.8%
Net income growth+44.8%-35.4%-12.4%+28.1%-29.5%+73.5%-
Revenue CAGR (3Y)-4.0%-2.2%+6.2%+19.4%+15.6%+23.9%+19.6%
EBITDA CAGR (3Y)-5.3%-4.3%-2.4%+19.3%+24.7%+43.2%+18.7%
Profitability & leverage
Net income margin+11.5%+10.5%+11.6%+12.7%+11.9%+17.6%+19.2%
Return on capital employed+12.5%+11.5%+16.9%+19.3%+16.1%+26.3%+16.3%
Return on net worth+10.3%+9.8%+15.0%+19.1%+16.5%+27.8%+19.7%
Debt / equity0.220.300.340.380.410.440.58
Long-term debt / equity0.020.020.040.080.120.190.28
Interest cover11.2215.0010.955.583.153.206.85
Efficiency & per share
Fixed asset turnover1.351.261.661.891.781.951.70
Inventory turnover5.454.946.416.646.157.787.02
Debtors turnover2.732.072.503.042.913.823.47
EPS (₹)16.1713.1717.9920.6115.5822.3217.47
Dividend per share (₹)1.751.501.501.501.501.501.00
Book value per share (₹)162.77140.31128.36111.53102.0487.3271.25

Investments & Acquisitions by Granules India

Granules India has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Auctus Pharma and Senn Chemicals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Senn Chemicals
Contract manufacturing for peptides, amino acid derivatives, carbohydrates, small molecules, etc
sennchem.comDielsdorf, Switzerland1963Feb 2025$22.2M
Auctus Pharma
Active pharmaceutical ingredients are manufactured by Auctus Pharma.
auctuspharma.comHyderabad, India2000Nov 2013$16.39M
Premium access

Complete acquisition details for Granules India

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Granules India

4 dated milestones of Granules India across 41 years, from founding to its latest funding, stage changes and deals.

  1. Founded Granules India is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Auctus Pharma.
  4. Acquisition Acquires Senn Chemicals.

Web traffic of Granules India

The website of Granules India (granulesindia.com) receives about 14.1K visits a month.

  • Monthly visits
    14.1K

    ▲ 23.2% vs previous month

Similar websites

Websites whose visitors overlap most with Granules India. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Jubilant Pharmova
jubilantpharmova.com
100%
7K#3,116,802View details
Jubilant Life Sciences
jubl.com
66%
48.5K#611,852View details
vramonline.wordpress.com
vramonline.wordpress.com
53%
–
Ramky
ramky.com
53%
9.9K#1,942,504View details
lotuscentre.ac.in
lotuscentre.ac.in
28%
#8,518,322–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 11 similar websites and full traffic analytics for Granules India

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Granules India (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Granules India

Granules India: US FDA Starts Inspection Of Granules India's Gagillapur Facility Today
Exchange Update • 13 days ago
Granules India: Co Says First-to-file Opportunities Are An Important Part Of Our Strategy To Build A More Differentiated And Higher-value Product Portfolio In The U.S
Exchange Update • 25 days ago
Granules India: Achieves Potential Sole First-To-File Status For Ruxolitinib Extended-Release Tablets ANDA.
Exchange Update • 25 days ago
Granules India: Company Plans ₹2,000 Crore Investment in Organic Growth Over 3-4 Years, Peptide CDMO Division Aims for $50 Million in Revenue in 3 Years and $100 Million in 5 Years.
Exchange Update • 26 days ago
Buy Granules India; target of Rs 1010: Choice Institutional Equities
Moneycontrol • 27 days ago
Granules India incorporates wholly owned subsidiary in Brazil - CNBC TV18
CNBCTV18 • 1 month ago
Trade Spotlight: How should you trade Castrol, Ramkrishna Forgings, Sapphire Foods, Jindal Saw, Granules India, and others on September 18?
Moneycontrol • 1 month ago
Granules India: Co-Promoter Group Completes ₹1,093 Crore Payment for Preferential Issue, 2.49 Crore Warrants Ready for Conversion.
Exchange Update • 1 month ago
Stocks to Watch Today (Sep 11): Vodafone Idea, Neogen Chemicals, KIMS, Granules India and more
ZEE Business • 1 month ago
Motilal Oswal bullish on Granules India, Titan as pharma, jewellery demand stays strong - CNBC TV18
CNBCTV18 • 1 month ago
Premium access

Complete news archive for Granules India

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Granules India

Granules India was founded in 1984.

Granules India is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

KVS Ram Rao is the CEO of Granules India, as recorded in our data.

Granules India has 6,170 employees.

The primary company behind Granules India, Granules India Limited, reported revenue of ₹5,386 Cr for FY 2026, up 20% year on year.

CDMO focused on manufacturing of active pharmaceutical ingredients. It offers a wide range of products include Paracetamol, Ibuprofen, Metformin, Guaifenesin, Methocarbamol, Pharmaceutical Formulation Intermediates and Finished Dosages.

Yes, Granules India is publicly traded on NSE under the ticker symbol GRANULES.

Granules India has made 2 acquisitions, including Auctus Pharma, and Senn Chemicals.

Granules India operates through Granules India Limited.

The legal entities of Granules India currently have 13 directors, including Arun Sawhney, Harsha Chigurupati, Chaitanya Tummala and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available